Novo Nordisk agreed to pay up to €1.165 billion ($1.3 billion) for a global license to Swedish biotech Nanexa's PharmaShell drug delivery technology, which could enable obesity medications requiring injections only once every few months. Nanexa shares surged more than 110% on the announcement.
The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.
A French randomized trial found that discontinuing statins in people aged 75 and older who were taking them for primary prevention showed non-inferiority to continuing the drugs in terms of all-cause mortality over 3 years. The findings support individualized decision-making for statin use in older adults without previous cardiovascular disease.
The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.
Multiple U.S. states are implementing measures to regulate pharmacy benefit management companies that oversee prescription drug coverage for health insurers, as part of efforts to reduce medication costs for consumers.
Americans are expected to spend more than $1 trillion on prescription drugs in 2026, according to a new report from the American Society of Health-System Pharmacists. The surge is largely attributed to the growing popularity of GLP-1 weight-loss drugs.
Scripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.
The White House is negotiating new drug-pricing agreements with smaller biotechnology companies facing the threat of 100% tariffs on imported medicines, according to multiple sources with knowledge of the meetings.
The Federal Trade Commission struck a proposed settlement with CVS over charges that its pharmacy benefit manager manipulated insulin prices and impeded patient access. The FTC estimates the settlement will save Americans up to $7 billion in out-of-pocket costs over 10 years.
